Novotech kicks off Phase Ib trials in Australia and NZ for OncoMed
Wednesday, 03 November, 2010
California-based biopharma company, OncoMed Pharmaceuticals, has announced it will run three Phase Ib clinical trials in Australia and New Zealand testing its humanised monoclonal antibody therapies for cancer.
The three separate trials, which have begun enrollment, are targeting patients pancreatic cancer, advanced colorectal cancer, and non-squamous non-small cell lung cancer (NSCLC).
OncoMed's treatments use monoclonal antibodies to target specific biologic pathways that are critical to tumour initiating cells, or so-called 'cancer stem cells'.
The trials will be run in Australia and New Zealand through the Sydney-based contract research organisation, Novotech.
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
COVID vaccine candidate protects against multiple variants
By targeting features shared by a range of coronaviruses, the vaccine is designed to offer...
